Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls

2006 ◽  
Vol 16 (3) ◽  
pp. 1130-1139 ◽  
Author(s):  
K. Bergmark ◽  
E. ÅVALL-LUNDQVIST ◽  
P. W. Dickman ◽  
L. Henningsohn ◽  
G. Steineck

The aim of the study was to acquire knowledge that can be used to refine radical hysterectomy to improve quality-of-life outcome. Data were collected in 1996–1997 by means of an anonymous postal questionnaire in a follow-up study of two cohorts (patients and population controls). We attempted to enroll all 332 patients with stage IB–IIA cervical cancer registered in 1991–1992 at the seven departments of gynecological oncology in Sweden and 489 population controls. Ninety three (37%) of the 256 women with a history of cervical cancer who answered the questionnaire (77%) were treated with surgery alone. Three-hundred fifty population controls answered the questionnaire (72%). Women treated with radical hysterectomy, as compared with controls, had an 8-fold increase in symptoms indicating lymphedema (25% reported distress due to lymphedema), a nearly 9-fold increase in difficult emptying of the bladder, and a 22-fold increase in the need to strain to initiate bladder evacuation. Ninety percent of the patients were not willing to trade off survival for freedom from symptoms. Avoiding to induce long-term lymphedema or bladder-emptying difficulties would probably improve quality of life after radical hysterectomy (to cure cervical cancer). Few women want to compromise survival to avoid long-term symptoms.

2018 ◽  
Vol 28 (4) ◽  
pp. 818-823 ◽  
Author(s):  
Francesco Plotti ◽  
Corrado Terranova ◽  
Stella Capriglione ◽  
Stefania Crispino ◽  
Alessandra Li Pomi ◽  
...  

AimsThe aim of this study was to evaluate long-term quality of life and urinary and sexual function in long-term cervical cancer survivors previously treated with radical hysterectomy (RH) type C2/type III.MethodsAll patients who presented at Campus Bio-Medico of Rome for RH type C2/type III for cervical cancer were considered eligible for this retrospective study protocol. We included exclusively patients with complete response to primary treatment with at least 36 months of follow up. Included subjects were interviewed with the European Organization for Research and Treatment of Cancer QLQ-CX24 Questionnaire, European Organization for Research and Treatment of Cancer QLQ-C30, and an Incontinence Impact Questionnaire 7.ResultsFrom January 2004 to June 2014, 251 patients affected by locally advanced cervical cancer were treated at Campus Bio-Medico of Rome treated with type C2/type III RH. At time point of March 2017, 90 patients were included with a mean age of 55.6 ± 8.5 years. The questionnaires were administered after a median follow-up of 49 months after the end of therapy. The symptoms of fatigue, nausea and vomiting, appetite loss, pain, insomnia, and dyspnea, as well as a negative financial impact, were reported as not frequent and rarely disabling. On the contrary, patients frequently reported gastrointestinal complaints. Diarrhea was present in 6% of patients and was referred as mild; constipation was present in 75% of women and was reported as mild in 30% of cases, moderate in 30%, and severe in 15%. Concerning sexual activity, data indicated a good level of sexual enjoyment with a slight worsening of sexual activity. Incontinence was reported in 28% of cases and appeared to be mild and rarely disabling (all mean values <2).ConclusionsWaiting for ongoing randomized controlled trials, this study confirmed that RH may be considered as a useful treatment plan, according to its negligible long-term impact on quality of life, urinary dysfunction, and sexual function.


Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 317
Author(s):  
Mihai Stanca ◽  
Dan Mihai Căpîlna ◽  
Cristian Trâmbițaș ◽  
Mihai Emil Căpîlna

(1) Background: Cervical cancer patients have been found to have worse quality of life (QoL) scores due to cancer treatment, not only when compared to the general population, but also when compared to other gynecological cancer survivors. In Eastern European developing countries, the health care system often cannot afford the uppermost standardized treatment for these patients. In the absence of a comparable study in our country, the authors’ aim for this retrospective cross-sectional observational study was to evaluate the overall survival (OS) and the QoL o cervical cancer survivors; (2) Methods: 430 patients were analyzed. The first objective is to evaluate the OS rates of patients with cervical cancer stages IA2 to IIB undergoing radical hysterectomy (RH) +/− neoadjuvant or adjuvant radiotherapy +/− chemoradiotherapy treatment combinations. The second objective is to assess their QoL, using two standardized questionnaires issued by the European Organisation for Research and Treatment of Cancer (EORTC), namely QLQ-C30 and QLQ-CX24. (3) Results: The mean age of the participants was 51 years (22–76) and the average follow-up time was 65 months (2–128). At the time of the analysis, 308 out of 430 patients were alive, with a mean five-year OS of 72.4%. The multivariate Cox regression analysis identified stage IIB, parametrial invasion, and the lymph node metastases as independent prognostic risk factors negatively impacting the OS. Of the 308 patients still alive at the time of the analysis, 208 (68%) answered the QoL questionnaires. The QLQ-C30 shows a good long-term Global QoL of 64.6 (median), good functioning scores, and a decent symptom scale value. However, the EORTC QLQ-CX24 showed high values of cervical cancer-specific symptoms, namely: lymphedema, peripheral neuropathy, severe menopausal symptoms, and distorted body-image perception. The results also indicate a significant decline in the quality of sexual life with a low sexual enjoyment and decreased level of sexual activities. (4) Conclusion: Despite a good OS, in this setting of patients, cervical cancer survivors have a modest QoL and sexual function. Our study may provide a comparison for future randomized, controlled trials in Eastern European countries needing to confirm these results.


2014 ◽  
Vol 8 (3) ◽  
pp. 419-426 ◽  
Author(s):  
Howard P. Greenwald ◽  
Ruth McCorkle ◽  
Kathy Baumgartner ◽  
Carolyn Gotay ◽  
Anne Victoria Neale

2005 ◽  
Vol 97 (2) ◽  
pp. 310-317 ◽  
Author(s):  
Lari Wenzel ◽  
Israel DeAlba ◽  
Rana Habbal ◽  
Brenda Coffey Kluhsman ◽  
Diane Fairclough ◽  
...  

2018 ◽  
Vol 13 (2) ◽  
pp. 60-62
Author(s):  
Kenusha Devi Tiwari ◽  
Aruna Karki ◽  
Ganesh Dangal ◽  
Hema Pradhan ◽  
Ranjana Shrestha ◽  
...  

Radiation therapy is an effective treatment for cervical cancer. However, of various complications, irradiation sometimes can cause formation of fistula between vagina and bladder and or rectum compromising the quality of life. Pelvic radiation is the primary cause of delayed vesicovaginal fistula with incidence of 13% in well-resourced countries and 0.2% in low resourced countries. Majority of them become apparent 1.5-2 years after completion of radiotherapy and can occur even up-to 20-30 years after the original insult. A 63 years’ female visited our outpatient department for involuntary loss of urine per vagina for 1.5 years. She had undergone radical hysterectomy and radiotherapy 16 years ago for an advanced cervical carcinoma. With positive dye test, she had vesicovaginal fistula with Goh classification of 1biii. She underwent simple fistula repair via vaginal approach. After three weeks of catheterization, successful closure was achieved.


2009 ◽  
Vol 18 (5) ◽  
pp. 655-661 ◽  
Author(s):  
Monina G. Bartoces ◽  
Richard K. Severson ◽  
Barbara Ann Rusin ◽  
Kendra L. Schwartz ◽  
Julie Joanne Ruterbusch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document